Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLEIPNIR-2: Mirivadelgat CNS penetration and target engagement in Parkinson’s disease
2025-523570-17-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Mirivadelgat with Placebo (2 arms). Primary endpoints: Safety and tolerability of Mirivadelgat, CNS penetration of Mirivadelgat metabolite AD-835 and 1 more. Planned start Jun 2026; status: authorised.
02
Drugs
mirivadelgat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-523570-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523570-17-00.